CPIX Fundamental Analysis - CUMBERLAND PHARMACEUTICALS

Fundamental Rating

CPIX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. While CPIX seems to be doing ok healthwise, there are quite some concerns on its profitability. CPIX has a valuation in line with the averages, but it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

CPIX had positive earnings in the past year.

CPIX had a positive operating cash flow in the past year.

In the past 5 years CPIX always reported negative net income.

CPIX had a positive operating cash flow in 4 of the past 5 years.

1.2 Ratios

With a decent Return On Assets value of -4.68%, CPIX is doing good in the industry, outperforming 75.26% of the companies in the same industry.

CPIX has a better Return On Equity (-11.43%) than 76.29% of its industry peers.

		Industry Rank	Sector Rank
ROA	-4.68%
ROE	-11.43%
ROIC	N/A

ROA(3y)-7.42%

ROA(5y)-5.97%

ROE(3y)-21.64%

ROE(5y)-16.04%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Gross Margin of CPIX (84.33%) is better than 90.21% of its industry peers.

In the last couple of years the Gross Margin of CPIX has remained more or less at the same level.

CPIX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	84.33%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y1.33%

GM growth 5Y1.04%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

CPIX does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for CPIX has been reduced compared to 1 year ago.

Compared to 5 years ago, CPIX has less shares outstanding

The debt/assets ratio for CPIX is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of 0.85, we must say that CPIX is in the distress zone and has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of 0.85, CPIX is in line with its industry, outperforming 56.70% of the companies in the same industry.

The Debt to FCF ratio of CPIX is 1.00, which is an excellent value as it means it would take CPIX, only 1.00 years of fcf income to pay off all of its debts.

CPIX has a Debt to FCF ratio of 1.00. This is amongst the best in the industry. CPIX outperforms 95.88% of its industry peers.

A Debt/Equity ratio of 0.18 indicates that CPIX is not too dependend on debt financing.

CPIX has a Debt to Equity ratio of 0.18. This is comparable to the rest of the industry: CPIX outperforms 46.91% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.18
Debt/FCF	1
Altman-Z	0.85

ROIC/WACCN/A

WACC9.28%

2.3 Liquidity

CPIX has a Current Ratio of 1.25. This is a normal value and indicates that CPIX is financially healthy and should not expect problems in meeting its short term obligations.

The Current ratio of CPIX (1.25) is worse than 77.84% of its industry peers.

A Quick Ratio of 1.09 indicates that CPIX should not have too much problems paying its short term obligations.

Looking at the Quick ratio, with a value of 1.09, CPIX is doing worse than 72.68% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	1.25
Quick Ratio	1.09

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 550.00% over the past year.

CPIX shows a small growth in Revenue. In the last year, the Revenue has grown by 5.82%.

CPIX shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.95% yearly.

EPS 1Y (TTM)550%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%420%

Revenue 1Y (TTM)5.82%

Revenue growth 3Y1.71%

Revenue growth 5Y1.95%

Sales Q2Q%37.76%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 27.08, the valuation of CPIX can be described as expensive.

80.41% of the companies in the same industry are more expensive than CPIX, based on the Price/Earnings ratio.

CPIX is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 26.82, which is the current average of the S&P500 Index.

		Industry Rank	Sector Rank
PE	27.08
Fwd PE	N/A

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, CPIX is valued cheaper than 82.47% of the companies in the same industry.

Based on the Price/Free Cash Flow ratio, CPIX is valued cheaper than 90.72% of the companies in the same industry.

		Industry Rank	Sector Rank
P/FCF	10.06
EV/EBITDA	14.56

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

CPIX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CUMBERLAND PHARMACEUTICALS

NASDAQ:CPIX (8/1/2025, 8:00:00 PM)

After market: 3.6481 +0.13 (+3.64%)

3.52

+0.07 (+2.03%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)05-06 2025-05-06/amc

Earnings (Next)08-05 2025-08-05/amc

Inst Owners28.76%

Inst Owner Change0%

Ins Owners3.45%

Ins Owner Change0%

Market Cap52.66M

Analysts43.33

Price TargetN/A

Short Float %0.07%

Short Ratio0.08

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	27.08
Fwd PE	N/A
P/S	1.28
P/FCF	10.06
P/OCF	9.71
P/B	1.84
P/tB	4.9
EV/EBITDA	14.56

EPS(TTM)0.13

EY3.69%

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)0.35

FCFY9.94%

OCF(TTM)0.36

OCFY10.3%

SpS2.75

BVpS1.92

TBVpS0.72

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-4.68%
ROE	-11.43%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	84.33%
FCFM	12.74%

ROA(3y)-7.42%

ROA(5y)-5.97%

ROE(3y)-21.64%

ROE(5y)-16.04%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y1.33%

GM growth 5Y1.04%

F-Score7

Asset Turnover0.59

Health

		Industry Rank	Sector Rank
Debt/Equity	0.18
Debt/FCF	1
Debt/EBITDA	1.78
Cap/Depr	3.02%
Cap/Sales	0.46%
Interest Coverage	N/A
Cash Conversion	184.56%
Profit Quality	N/A
Current Ratio	1.25
Quick Ratio	1.09
Altman-Z	0.85

F-Score7

WACC9.28%

ROIC/WACCN/A

Cap/Depr(3y)16.58%

Cap/Depr(5y)20.37%

Cap/Sales(3y)2.19%

Cap/Sales(5y)2.64%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)550%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%420%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)5.82%

Revenue growth 3Y1.71%

Revenue growth 5Y1.95%

Sales Q2Q%37.76%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y50.05%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y5.15%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-24.53%

OCF growth 3YN/A

OCF growth 5YN/A

CUMBERLAND PHARMACEUTICALS (CPIX) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens